13 documents found, page 1 of 2
Detection of copy number variants in the human genome: Is long-read sequencing ...
Silva, Catarina; Ferrão, José; Marques, Barbara; Pedro, Sónia; Correia, Hildeberto; Rodrigues, António Sebastião; Vieira, LuísIntroduction: Copy number variations (CNVs) represent ~13% of the human genome and can harbour important genes and regulatory elements. High-resolution whole genome microarray (MA) analysis is the gold standard tool for detection of CNVs associated with genetic disorders. While short-read sequencing (SRS) can address SV detection, the use of long-read sequencing as proven to overcome SRS mapping inaccuracy in h...
SVInterpreter: a web-based tool for structural variants inspection and identifi...
Fino, Joana; Marques, Barbara; Dong, Zirui; David, DezsoIntroduction: With the advent of genomic sequencing, the identification of structural variants (SVs) is no longer a challenge, being possible to detect an average of 5 K SVs by individual. Contrarily, the annotation of the genome is incomplete, and the data is scattered along different databases, making SV manual evaluation complicated and time-consuming. Also, the available tools are limited on their scope. Th...
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the Euro...
Bellini, Angela; Pötschger, Ulrike; Bernard, Virginie; Lapouble, Eve; Baulande, Sylvain; Ambros, Peter F.; Auger, Nathalie; Beiske, KlausPurpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. Materials and methods: Diagnostic tumor samples were available from 1,092 H...
SVInterpreter: A Comprehensive Topologically Associated Domain-Based Clinical O...
Fino, Joana; Marques, Barbara; Dong, Zirui; David, DezsoWith the advent of genomic sequencing, a number of balanced and unbalanced structural variants (SVs) can be detected per individual. Mainly due to incompleteness and the scattered nature of the available annotation data of the human genome, manual interpretation of the SV’s clinical significance is laborious and cumbersome. Since bioinformatic tools developed for this task are limited, a comprehensive tool to a...
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectab...
Ambros, Inge M.; Tonini, Gian-Paolo; Pötschger, Ulrike; Gross, Nicole; Mosseri, Véronique; Beiske, Klaus; Berbegall, Ana P.; Bénard, Jean; Bown, NickPurpose: For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome. Patients and methods: Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/...
9q21.13q21.31 deletion in a patient with intellectual disability severe speech ...
Marques, Barbara; Serafim, Silvia; Pedro, Sonia; Tarelho, Ana Rita; Ferreira, Cristina; Gonçalves, Rui; Correia, HildebertoThe increased use of chromosomal microarray analysis has led to the identification of new microdeletion/microduplication syndromes, enabling better genotype-phenotype correlations. Interstitial deletions involving the long arm of chromosome 9 are rare but recently a microdeletion syndrome at 9q21.13 was suggested, with mental retardation, speech delay, epilepsy, autistic behaviour and moderate facial dysmorphis...
Genetic alterations of ALK in high-risk neuroblastoma patients. A SIOPEN study
Bellini, Angela; Bernard, Virginie; Ambros, Inge; F. Ambros, Peter; de Preter, Katleen; Combaret, Valérie; Beiske, Klaus; Jeison, MartaBackground: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through genomic amplification or activating point mutations. We studied ALK genetic alterations in high-risk NB patients to determine their frequency and prognostic impact. Methods: Diagnostic NB samples from 1039 patients enrolled in the SIOPEN-HR-NBL1 trial were studied to determine the ALK amplification status...
Susceptibility loci CNVs with incomplete penetrance accurate diagnosis with unc...
Serafim, Silvia; Marques, Barbara; Correia, HildebertoChromosomal microarray analysis (CMA) is the first-tier test for developmental delay, autism spectrum disorders, and congenital abnormalities in postnatal diagnosis and for ultrasound abnormalities in prenatal diagnosis. The detection of variants with clinical significance by CMA, when compared to karyotype, can increase up to 10-20% in postnatal diagnosis and up to 5-18% in prenatal diagnosis. Nevertheless CMA...
Genetic alterations of ALK in high-risk neuroblastoma patients: a SIOPEN study
Bellini, Angela; Bernard, Virginie; Ambros, Inge; Ambros, Peter F.; de Preter, Katleen; Combaret, Valérie; Beiske, Klaus; Jeison, MartaBackground: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated either through genomic amplification or activating point mutations. We studied ALK genetic alterations in high-risk NB patients to determine their frequency and prognostic impact.
Small Deletion of 143 Kb Encompassing Exon 2 of the AUTS2: Rise of a NewMicrode...
Serafim, Silvia; Marques, Barbara; Filomena, Brito; Pedro, Sónia; Ferreira, Cristina; Ventura, Catarina; Gaspar, Isabel; Correia, HildebertoChromosome microarray analysis is a powerful diagnostic tool and is being used as a first-line approach to detect chromosome imbalances associated with intellectual disability, dysmorphic features and congenital anomalies. This test enables the identification of new copy number variants (CNVs) and their association with new microdeletion/microduplication syndromes in patients previously without diagnosis. Here ...